This bill amends existing law to allow alternative treatment centers to utilize specific cannabis products for therapeutic purposes. It modifies the definition of "cannabis" in RSA 126-X:1, III, to clarify that it encompasses all parts of the Cannabis genus, excluding mature stalks, fiber, oil, cake made from seeds, and sterilized seeds incapable of germination. Notably, the bill specifies that cannabis does not include hemp grown, processed, marketed, or sold under RSA 439-A, except as outlined in RSA 126-X:8, XIX.

Additionally, the bill introduces new provisions in RSA 126-X:8, allowing alternative treatment centers to acquire and use non-intoxicating cannabinoids derived from hemp, as well as to manufacture cannabis concentrates and cannabis-infused products. However, it prohibits the use of hemp-derived products containing natural THC greater than 0.3 percent, including any formulations of delta-8 THC, delta-9 THC, or synthetic THC. The act is set to take effect 60 days after its passage.

Statutes affected:
Introduced: 126-X:1, 126-X:8
SB650 text: 126-X:1, 126-X:8